Involvement of cyclin B1 in progesterone-mediated cell growth inhibition, G2/M cell cycle arrest, and apoptosis in human endometrial cell

Reproductive Biology and Endocrinology

Volumn 7, Issue , 2009, Pages

  Tang, Li ^a,c   Zhang, Yu ^a   Pan, Hong ^a   Luo, Qiong ^a   Zhu, Xiao Ming ^a   Dong, Min Yue ^a   Leung, Peter C K ^b   Sheng, Jian Zhong ^a   Huang, He Feng ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c FIRST PEOPLE S HOSPITAL OF YUNNAN PROVINCE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALSTERPAULLONE; CYCLIN B1; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PROGESTERONE; PROPIDIUM IODIDE; BENZAZEPINE DERIVATIVE; COLORING AGENT; INDOLE DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ADULT; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOMETRIUM CELL; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HORMONE ACTION; HUMAN; HUMAN CELL; MENSTRUAL CYCLE; MITOSIS INHIBITION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; CELL DIVISION; CYTOLOGY; DRUG EFFECT; ENDOMETRIUM; IN VITRO STUDY; PHYSIOLOGY;

ADULT; APOPTOSIS; BENZAZEPINES; BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CELLS, CULTURED; COLORING AGENTS; CYCLIN B1; ENDOMETRIUM; FEMALE; FLOW CYTOMETRY; G2 PHASE; HUMANS; INDOLES; PROGESTERONE; TETRAZOLIUM SALTS; THIAZOLES;

EID: 73349124117     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-7-144     Document Type: Article

References (33)

1. Druckmann R. Long-term use of progestogens--getting the balance right: molecular biology and the endometrium. Gynecol Endocrinol 2007, 23(Suppl 1):53-61. 10.1080/09513590701585045, 17943540.
2. Strausfeld U, Labbe JC, Fesquet D, Cavadore JC, Picard A, Sadhu K, Russell P, Doree M. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 1991, 351:242-245. 10.1038/351242a0, 1828290.
3. Lindahl B, Willen R. Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients. Anticancer Res 1991, 11:403-406.
4. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997, 90:434-440. 10.1016/S0029-7844(97)00297-4, 9277658.
5. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999, 17:1736-1744.
6. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003, 91:526-533. 10.1016/j.ygyno.2003.07.002, 14675671.
7. Phillips V, Graham CT, Manek S, McCluggage WG. The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. J Clin Pathol 2003, 56:305-307. 10.1136/jcp.56.4.305, 1769918, 12663645.
8. Hapgood JP, Koubovec D, Louw A, Africander D. Not all progestins are the same: implications for usage. Trends Pharmacol Sci 2004, 25:554-557. 10.1016/j.tips.2004.09.005, 15491776.
9. Fujishita A, Nakane PK, Koji T, Masuzaki H, Chavez RO, Yamabe T, Ishimaru T. Expression of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: an immunohistochemical and in situ hybridization study. Fertil Steril 1997, 67:856-864. 10.1016/S0015-0282(97)81397-0, 9130890.
10. Nishimura R, Saeki T, Ohsumi S, Tani Y, Takashima S. Immunohistochemical expression of hormone receptors and the histological characteristics of biochemically hormone receptor negative breast cancers. Breast Cancer 2007, 14:100-104. 10.2325/jbcs.14.100, 17245003.
11. Gein SV, Baeva TA, Kichanova OA. Effect of beta-endorphin on production of antibodies and IL-4 under conditions of opioid receptor blockade. Bull Exp Biol Med 2006, 142:226-229. 10.1007/s10517-006-0334-6, 17369946.
12. Rutanen EM. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery. Hum Reprod 2000, 15(Suppl 3):173-181.
13. Shiozawa T, Nikaido T, Nakayama K, Lu X, Fujii S. Involvement of cyclin-dependent kinase inhibitor p27Kip1 in growth inhibition of endometrium in the secretory phase and of hyperplastic endometrium treated with progesterone. Mol Hum Reprod 1998, 4:899-905. 10.1093/molehr/4.9.899, 9783852.
14. Jackman M, Lindon C, Nigg EA, Pines J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 2003, 5:143-148. 10.1038/ncb918, 12524548.
15. Jin P, Hardy S, Morgan DO. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 1998, 141:875-885. 10.1083/jcb.141.4.875, 2132764, 9585407.
16. Grabsch H, Lickvers K, Hansen O, Takeno S, Willers R, Stock W, Gabbert HE, Mueller W. Prognostic value of cyclin B1 protein expression in colorectal cancer. Am J Clin Pathol 2004, 122:511-516. 10.1309/54H4Q88A1UBBWPTE, 15487447.
17. Shiozawa T, Li SF, Nakayama K, Nikaido T, Fujii S. Relationship between the expression of cyclins/cyclin-dependent kinases and sex-steroid receptors/Ki67 in normal human endometrial glands and stroma during the menstrual cycle. Mol Hum Reprod 1996, 2:745-752. 10.1093/molehr/2.10.745, 9239692.
18. Milde-Langosch K, Bamberger AM, Goemann C, Rossing E, Rieck G, Kelp B, Loning T. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 2001, 127:537-544. 10.1007/s004320100256, 11570574.
19. Tong W, Pollard JW. Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol Cell Biol 1999, 19:2251-2264. 84018, 10022912.
20. Korgun ET, Celik-Ozenci C, Acar N, Cayli S, Desoye G, Demir R. Location of cell cycle regulators cyclin B1, cyclin A, PCNA, Ki67 and cell cycle inhibitors p21, p27 and p57 in human first trimester placenta and deciduas. Histochem Cell Biol 2006, 125:615-624. 10.1007/s00418-006-0160-y, 16491347.
21. Lee WS, Liu CW, Juan SH, Liang YC, Ho PY, Lee YH. Molecular mechanism of progesterone-induced antiproliferation in rat aortic smooth muscle cells. Endocrinology 2003, 144:2785-2790. 10.1210/en.2003-0045, 12810531.
22. Tang L, Wang TT, Wu YT, Zhou CY, Huang HF. High expression levels of cyclin B1 and Polo-like kinase 1 in ectopic endometrial cells associated with abnormal cell cycle regulation of endometriosis. Fertil Steril 2009, 91:979-987. 10.1016/j.fertnstert.2008.01.041, 18353325.
23. Tsuda H, Hashiguchi Y, Inoue T, Yamamoto K. Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology 2003, 65:159-166. 10.1159/000072342, 12931023.
24. Rudolph P, Kuhling H, Alm P, Ferno M, Baldetorp B, Olsson H, Parwaresch R. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 2003, 105:674-680. 10.1002/ijc.11132, 12740917.
25. Chen B, Pan H, Zhu L, Deng Y, Pollard JW. Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase-->AKT-->GSK-3beta-->cyclin D1-->pRB pathway to block uterine epithelial cell proliferation. Mol Endocrinol 2005, 19:1978-1990. 10.1210/me.2004-0274, 15845746.
26. Ohta K, Maruyama T, Uchida H, Ono M, Nagashima T, Arase T, Kajitani T, Oda H, Morita M, Yoshimura Y. Glycodelin blocks progression to S phase and inhibits cell growth: a possible progesterone-induced regulator for endometrial epithelial cell growth. Mol Hum Reprod 2008, 14:17-22. 10.1093/molehr/gam081, 18178606.
27. Paulssen RH, Moe B, Gronaas H, Orbo A. Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids 2008, 73:116-128. 10.1016/j.steroids.2007.09.010, 18037150.
28. Matsumoto Y, Iwasaka T, Yamasaki F, Sugimori H. Apoptosis and Ki-67 expression in adenomyotic lesions and in the corresponding eutopic endometrium. Obstet Gynecol 1999, 94:71-77. 10.1016/S0029-7844(99)00279-3, 10389721.
29. Soni DV, Jacobberger JW. Inhibition of cdk1 by alsterpaullone and thioflavopiridol correlates with increased transit time from mid G2 through prophase. Cell Cycle 2004, 3:349-357.
30. Lahusen T, De Siervi A, Kunick C, Senderowicz AM. Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential. Mol Carcinog 2003, 36:183-194. 10.1002/mc.10114, 12669310.
31. Borgne A, Versteege I, Mahe M, Studeny A, Leonce S, Naime I, Rodriguez M, Hickman JA, Meijer L, Golsteyn RM. Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment. Oncogene 2006, 25:7361-7372. 10.1038/sj.onc.1209718, 16785996.
32. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004, 10:4270s-4275s. 10.1158/1078-0432.CCR-040020, 15217973.
33. Schultz C, Link A, Leost M, Zaharevitz DW, Gussio R, Sausville EA, Meijer L, Kunick C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem 1999, 42:2909-2919. 10.1021/jm9900570, 10425100.